Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Plinabulin - BeyondSpring Pharmaceuticals

Drug Profile

Plinabulin - BeyondSpring Pharmaceuticals

Alternative Names: BPI 2358; NPI 2358

Latest Information Update: 10 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nereus Pharmaceuticals
  • Developer BeyondSpring Pharmaceuticals; Big Ten Cancer Research Consortium; National Cancer Institute (USA); Nereus Pharmaceuticals; Rutgers Cancer Institute of New Jersey; University of Washington
  • Class Antineoplastics; Imidazoles; Piperazines; Small molecules
  • Mechanism of Action Guanine nucleotide exchange factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Neutropenia; Non-small cell lung cancer
  • Phase I/II Small cell lung cancer
  • Preclinical Glioblastoma
  • Research Brain cancer
  • No development reported Solid tumours

Most Recent Events

  • 21 Dec 2018 USPTO issues a new composition of matter patent to plinabulin in USA
  • 01 Dec 2018 Updated efficacy data from the phase II/III Protective 1 trial in Neutropenia (Chemotherapy-induced, Combination therapy, Prevention) presented at the 60th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem-2018)
  • 27 Nov 2018 BeyondSpring Pharmaceuticals has patent protection for plinabulin in Chemotherapy induced neutropenia (CIN) in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top